Deutsch Manfred, Meinhart Johann, Zilla Peter, Howanietz Norbert, Gorlitzer Michael, Froeschl Alexander, Stuempflen Andreas, Bezuidenhout Deon, Grabenwoeger Martin
Department of Cardiovascular and Thoracic Surgery, Hospital Hietzing, Vienna, Austria.
J Vasc Surg. 2009 Feb;49(2):352-62; discussion 362. doi: 10.1016/j.jvs.2008.08.101. Epub 2008 Dec 25.
Based on a previous randomized study showing significantly superior patency rates for in vitro endothelialized expanded polytetrafluoroethylene (ePTFE) grafts we investigated whether it was feasible for a nontertiary institution to offer autologous in vitro endothelialization to all elective infrainguinal bypass patients who had no suitable saphenous vein available.
Over a period of 15 years, 310 out of 318 consecutive nonacute patients (age 64.7 +/- 8.6) received 341 endothelialized ePTFE grafts (308 femoropopliteal: 153 above knee [AK] and 155 below knee [BK] and 33 femorodistal). Autologous endothelial cells were harvested from short segments (3.9 +/- 1.1 cm) of subcutaneous veins (80% cephalic, 11% basilic, 2% external jugular, and 7% saphenous) and grown to mass cultures within 18.9 +/- 4.5 days before being confluently lined onto fibrin glue-coated ePTFE grafts. The graft diameter was 6 mm (64%) or 7 mm (36%). The overall procedure-related delay for graft implantation was 27.6 + 7.8 days. Growth failure prevented 2.5% of patients from receiving an endothelialized graft. The mean observation period was 9.6 years. Primary patencies were obtained from Kaplan-Meier survivorship functions. Explants for morphological analysis were obtained from eight patients.
The overall primary patency rate of femoropopliteal grafts was 69% at 5 years (68% [AK] vs 71% [BK]) and 61% at 10 years (59% [AK] vs 64% [BK]). Primary patency of 7 mm vs 6 mm grafts was 78%/62% at 5 years and 71%/55% at 10 years. The difference between the two groups was statistically significant (log rank test P = .023; Breslow test P = .017). Stage I vs II/III patients showed 5-year patencies of 67% vs 73% (N.S.) and 10-year patencies of 61%% vs 53% (N.S.). The primary patency of femorodistal grafts was 52% at 5 years and 36% at 10 years. The limb salvage rate was 94% (fempop) vs 86% (femdistal) at 5 years and 89% vs 71% at 10 years. All retrieved samples showed the presence of an endothelium after 38.9 +/- 17.8 months.
Autologous in vitro endothelialization was shown to be a feasible routine procedure at a nontertiary hospital. Explants confirmed the presence of an endothelium years after implantation while the primary patency in the particularly challenging subgroup of patients without a suitable saphenous vein resembles that of vein grafts.
基于先前的一项随机研究表明体外内皮化的膨体聚四氟乙烯(ePTFE)移植物的通畅率显著更高,我们调查了对于没有合适大隐静脉可用的所有择期腹股沟下旁路手术患者,非三级医疗机构提供自体体外内皮化是否可行。
在15年期间,318例连续的非急性患者(年龄64.7±8.6岁)中的310例接受了341个内皮化的ePTFE移植物(308个股腘动脉移植物:153个膝上[AK]和155个膝下[BK],以及33个股远端移植物)。自体内皮细胞从皮下静脉的短节段(3.9±1.1厘米)获取(80%为头静脉,11%为贵要静脉,2%为颈外静脉,7%为大隐静脉),并在18.9±4.5天内培养至大量培养物,然后汇合排列在纤维蛋白胶包被的ePTFE移植物上。移植物直径为6毫米(64%)或7毫米(36%)。移植物植入的总体与手术相关的延迟为27.6 + 7.8天。生长失败使2.5%的患者无法接受内皮化移植物。平均观察期为9.6年。主要通畅率通过Kaplan-Meier生存函数获得。从8例患者获取用于形态学分析的移植物标本。
股腘动脉移植物的总体主要通畅率在5年时为69%(膝上为68%,膝下为71%),在10年时为61%(膝上为59%,膝下为64%)。7毫米与6毫米移植物的主要通畅率在5年时为78%/62%,在10年时为71%/55%。两组之间的差异具有统计学意义(对数秩检验P = 0.023;Breslow检验P = 0.017)。I期与II/III期患者的5年通畅率分别为67%和73%(无统计学差异),10年通畅率分别为61%和53%(无统计学差异)。股远端移植物的主要通畅率在5年时为52%,在10年时为36%。5年时肢体挽救率股腘动脉移植物为94%,股远端移植物为86%;10年时分别为89%和71%。所有回收的标本在38.9±17.8个月后显示存在内皮。
自体体外内皮化在非三级医院被证明是一种可行的常规手术。移植物标本证实植入多年后存在内皮,而在没有合适大隐静脉的特别具有挑战性的患者亚组中,主要通畅率与静脉移植物相似。